Seeking Alpha

Fresh off its acquisition of Obagi Medical, Valeant Pharmaceuticals (VRX) is reportedly in talks...

Fresh off its acquisition of Obagi Medical, Valeant Pharmaceuticals (VRX) is reportedly in talks to buy Actavis (ACT) for $13B in a deal billed as a "merger of equals" that would pay ACT shareholders a slight premium. Earlier this month, the two companies settled patent litigation surrounding NDA applications for generic versions of Zyclara and Ziana. Asked for comment, a Valeant spokesperson tells WSJ only: "We're a very acquisitive company."
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|